Comparison of Endostar continuous versus intermittent intravenous infusion in combination with first-line chemotherapy in patients with advanced non-small cell lung cancer.

Yuan ChengLigong NieYing LiuZhe JinXi WangZhanwei Hu

Published in: Thoracic cancer (2019)

CI of Endostar combined with first-line chemotherapy for advanced NSCLC had similar progression-free survival, objective response, and overall response rates as II, with tolerable adverse effects.

Keyphrases

advanced non small cell lung cancer
free survival
epidermal growth factor receptor
locally advanced
small cell lung cancer
low dose
high dose
high intensity
rectal cancer